Numab Therapeutics
Numab Therapeutics is a clinical-stage biotech company developing multi-specific antibody-based immunotherapies for inflammation and cancer. They utilize proprietary technology platforms, λ-CapTM and MATCHTM, to overcome drug discovery challenges and build a pipeline of novel medicines. Their lead asset, NM32, is currently in Phase 1 trials.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $55M
Date: 10-Jan-2025
Investors: Cormorant Asset Management, Forbion, HBM Healthcare Investment, Novo Holdings, BVF Partners LP, Octagon Capital Advisors LP, RTW Investments, BlackRock
Markets: Biotech, Oncology, Immunology, Biotechnology Research, Health Care, Health Diagnostics, Life Science, Medical, Therapeutics
HQ: Horgen, Switzerland
Founded: 2011
Website: https://www.numab.com/
LinkedIn: https://www.linkedin.com/company/numab-ag
Twitter: https://twitter.com/numab_tx
Crunchbase: https://www.crunchbase.com/organization/numab-ag
Leave a Comment
Comments
No comments yet.